© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Sunitinib goes by the molecular formula C22H27FN4O2 and it carries a molecular weight of 398.48 g/mol. This small-molecule compound shows up in cancer therapy as a tyrosine kinase inhibitor, but before it reaches a patient, it takes shape as a physical substance handled by researchers, chemists, and industry professionals. In its raw state, Sunitinib appears as a yellow or yellowish-brown crystalline powder. This powdered solid often clumps or forms loose flakes, which tells you a lot about its density and handling requirements. While it looks pretty unremarkable, Sunitinib’s molecular structure features a fluorinated aromatic core, giving it distinctive chemical reactivity. HS Code for Sunitinib falls under 2933990099, matching it as an organic compound within pharmaceutical categories.
Sunitinib presents itself in several physical forms, usually as powder or fine flakes at laboratory or manufacturing scale. The powder’s density sits around 1.07 g/cm3. In water, it barely dissolves, so organic solvents such as dimethyl sulfoxide (DMSO) and dimethylformamide (DMF) are the go-tos for getting it into solution. Its limited solubility means handling requires containment and sometimes a dust mask, keeping fine particulates out of the air. Sunitinib burns at fairly high temperatures above 200°C, staying stable at room temperature in both solid and solution states for months when kept away from sunlight and moisture. Chemists often rely on its stable, crystalline nature for storage and dispensing, as the powder maintains integrity under standard lab humidity.
This molecule includes an indole core fused with a pyrrole ring and attached to a fluorophenyl group. That blend creates both rigidity and reactivity—pharmacologically, these features matter, but they also dictate how it’s processed in chemical synthesis and as a raw material. The melting point stands at about 225°C. Its color, shifting from light to dark yellow, stems from extended conjugation in the aromatic system. Because of low vapor pressure, it doesn’t easily turn to gas, so most industrial action happens in the solid or dissolved state. If you look at the material under a microscope, particles tend to have jagged, irregular faces, not perfectly round or pearl-like forms. This trait comes from the rapid crystallization during production.
High-purity Sunitinib lands between 98% and 99.5%, measured by HPLC with specific standards. Impurities, both known and unknown, must stay below 0.5% for pharmaceutical use. It counts as a hazardous chemical through skin and respiratory exposure, irritating mucous membranes and sometimes classified as harmful if swallowed or inhaled. Handling calls for nitrile gloves and safety glasses in most labs, with powder containment hoods protecting from airborne dust. Its physical form—powder—dictates loading, storage, and transport, requiring solid, tamper-proof containers labeled for chemical risk and batch traceability.
Sunitinib’s chemical stability lets it ship at ambient temperature, but material safety data sheets highlight risks—especially for those handling bulk powder. Low volatility means inhalation isn’t as likely as skin contact, yet accidents can happen, so work habits rely on closed systems and sealed scoops. Sunitinib does not produce significant hazardous gases on breakdown, yet incineration or high heat may release noxious compounds, demanding well-ventilated disposal procedures. Its solid density—about 1.07 g/cm3—helps estimate storage volume and dosing accuracy in compounding.
Safe management of Sunitinib starts with clear regulations and strict adherence to guidelines set by agencies like the U.S. Occupational Safety and Health Administration (OSHA) and the European Chemicals Agency (ECHA). Training plays a pivotal role—building habits so no one forgets gloves, eye shields, or fume hoods, especially with a compound identified as hazardous and potentially harmful. Raw material tracking ties into broader pharmaceutical compliance, where digital batch records document every transfer or aliquot. Improved labeling, better supply chain monitoring, and investment in containment can cut both safety risks and losses from contamination. Chemical manufacturers and research facilities must look at safer packaging innovations, such as single-use sterile bottles or powder pre-loading systems, which reduce direct handling. Regular safety drills, transparent incident reporting, and collaboration with chemical suppliers support a stronger safety culture around this and other hazardous materials.
